Financial Performance & Outlook - Revenue for Q1 2025 was $40.8 million[10] - The company is targeting revenue in the range of $165 million to $175 million for 2025[10] - Non-GAAP operating expenses decreased by 22% year-over-year in Q1 2025[10, 17, 53] - Adjusted EBITDA improved by 29% year-over-year in Q1 2025[10, 17, 58] - Non-GAAP Gross Margin was 53% in Q1 2025[49] Cash Position & Cost Reduction - The company had $261 million in cash, cash equivalents, restricted cash, and short-term investments as of March 31, 2025[10, 22, 62] - The company operationalized approximately $10 million in cost reductions in Q1 2025, totaling $90 million since the merger[10] Strategic Initiatives - The company is rolling out new proteomics solutions and Illumina NGS[10] - The company is targeting adjusted EBITDA positive in 2026[10, 19, 64] SomaLogic Merger - The company is targeting $80 million in synergies from the SomaLogic merger[19, 22]